In this article, we introduce and apply our de novo protein design framework, which observes true backbone flexibility, to the redesign of human beta-defensin-2, a 41-residue cationic antimicrobial peptide of the innate immune system. The flexible design templates are generated using molecular dynamics simulations with both Generalized Born implicit solvation and explicit water molecules. These backbone templates were employed in addition to the x-ray crystal structure for designing human beta-defensin-2. The computational efficiency of our framework was demonstrated with the full-sequence design of the peptide with flexible backbone templates, corresponding to the mutation of all positions except the native cysteines.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2157230 | PMC |
http://dx.doi.org/10.1529/biophysj.107.110627 | DOI Listing |
Pathogens
December 2024
M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
Today, is still the most common cause of both local and life-threatening systemic candidiasis. The spread of resistant fungal strains has resulted in an urgent need to search for new promising antimycotics. Here, we investigated the antifungal action of the tobacco defensin NaD1 against susceptible and resistant to azoles and echinocandins strains of .
View Article and Find Full Text PDFJ Clin Med
December 2024
Department of Pulmology, Special Hospital for Pulmonary Diseases, 10000 Zagreb, Croatia.
: Human β-defensin 2 (HBD2) is a protein that plays an important role in activating the immune system by modulating spinal pathways and the inflammatory response. According to previous research, HBD2 was proven to be important in chronic spontaneous urticaria (CSU) (their values were significantly elevated in CSU patients, with a significant correlation between HBD2 levels and the percentage of peripheral basophils, suggesting that elevated HBD2 levels may be a potential marker of basophil and mast cell activation), which led us to additional research on the HBD2 molecule in isolated chronic angioedema. The aim of this research is to examine HBD2 values in the saliva and serum of patients with isolated angioedema, as a potential biomarker of the disease.
View Article and Find Full Text PDFAntibiotics (Basel)
November 2024
M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
Defensins are important components of the innate plant immune system, exhibiting antimicrobial activity against phytopathogens, as well as against fungi pathogenic to humans. Along with antifungal activity, plant defensins are also capable of influencing various immune processes, but not much is known about these effects. In this study, we investigated the immunomodulatory effects of the tobacco defensin NaD1, which possesses a pronounced antifungal activity.
View Article and Find Full Text PDFClin Oral Investig
November 2024
Department of Periodontology and Operative Dentistry, University Medical Center of the Johannes Gutenberg University, 55131, Mainz, Germany.
Objectives: The present study aimed to investigate a possible immunomodulatory role of the periodontopathogen Filifactor alocis through the antimicrobial peptide hBD-2 on the expression of chemokines in human gingival keratinocytes.
Materials And Methods: Cells were cultured in the presence or absence of periodontopathogenic bacteria, such as F. alocis, Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, and Treponema denticola, to evaluate the regulation of hBD-2, CXCL8 and CCL20.
Ther Adv Musculoskelet Dis
October 2024
Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Division of Rheumatology, Memorial University of Newfoundland, St John's, Canada.
Background: Guselkumab (human monoclonal antibody) selectively inhibits the interleukin (IL)-23p19 subunit.
Objectives: Assess the longer-term pharmacodynamic effects of guselkumab and explore associations between such effects and clinical responses in patients with active psoriatic arthritis (PsA).
Design: DISCOVER-2 randomized 739 biologic-naïve patients with active PsA (swollen/tender joint counts each ⩾5, C-reactive protein (CRP) ⩾0.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!